Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
Copyright © 2023 Science China Press. Published by Elsevier B.V. All rights reserved..
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Science bulletin - 68(2023), 23 vom: 15. Dez., Seite 3003-3012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Shixiong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.scib.2023.09.048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364110325 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364110325 | ||
| 003 | DE-627 | ||
| 005 | 20231227140919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.scib.2023.09.048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM364110325 | ||
| 035 | |a (NLM)37919162 | ||
| 035 | |a (PII)S2095-9273(23)00683-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Shixiong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Classification of five SARS-CoV-2 serotypes based on RBD antigenicities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Science China Press. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Receptor-binding domain (RBD) | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Serotype classification | |
| 650 | 4 | |a Spike (S) | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Wu, Chunli |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xinkai |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xuehui |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Anqi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huiting |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, George Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qihui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science bulletin |d 2015 |g 68(2023), 23 vom: 15. Dez., Seite 3003-3012 |w (DE-627)NLM249522675 |x 2095-9281 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2023 |g number:23 |g day:15 |g month:12 |g pages:3003-3012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.scib.2023.09.048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2023 |e 23 |b 15 |c 12 |h 3003-3012 | ||